Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Phenibut | Phenylpiracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk) | 100-300 mg/day divided into 1-2 doses |
| Timing | On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours. | Morning or early afternoon; avoid evening use due to stimulant effects. Take with or without food. |
| Cycle Duration | STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence. | Use sparingly — tolerance develops rapidly. Best cycled 2 weeks on, 2 weeks off, or reserved for acute-need situations. |
| Evidence Level | moderate_human | moderate_human |
Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.
250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)
On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.
STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.
Atypical dopamine reuptake inhibitor with additional phenethylamine-like stimulatory properties. Increases the density of acetylcholine, NMDA, GABA, and dopamine receptors in the brain. The phenyl group addition to the piracetam backbone enables blood-brain barrier penetration at 20-60x greater potency than piracetam, with added psychostimulant and cold-tolerance properties.
100-300 mg/day divided into 1-2 doses
Morning or early afternoon; avoid evening use due to stimulant effects. Take with or without food.
Use sparingly — tolerance develops rapidly. Best cycled 2 weeks on, 2 weeks off, or reserved for acute-need situations.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →